Category: CannabisNewsWire Release

420 with CNW — Voters in Oklahoma to Decide Whether to Legalize Recreational Marijuana

Voters in Oklahoma are on track to vote on legislation that would legalize recreational cannabis in the state. On March 7, 2023, Oklahomans will get the chance to vote for or against state question 820, which asks if voters would like to expand the state’s medical cannabis industry to include adult-use cannabis.

If Oklahomans vote in favor of the measure, Oklahoma will become the 22nd  state in the nation to put a stop to marijuana prohibition.

The measure comes close to five years after Oklahoma residents turned out in record numbers to vote in favor of legalizing medical cannabis. Activists behind the legislation had tried to place the adult-use cannabis issue on the November 2022 ballot, but their efforts were unsuccessful after complaints at the Supreme Court caused them to miss deadlines.

In mid-October, Governor Kevin Stitt issued a proclamation stating that Oklahomans would get to vote on cannabis legalization during a special election in March.

State question 820 would make it legal for adults aged 21 years old and over to purchase and possess up to an ounce of marijuana. Adults would also be allowed to grow up to six seedlings and six mature cannabis plants at home for personal use. The Oklahoma Medical Marijuana Authority would be charged with regulating the new adult-use industry as well as issuing businesses with recreational cannabis licenses.

Recreational cannabis sales would be subject to a 15% excise tax, and the revenue generated from the tax will be put into an Oklahoma Marijuana Revenue Trust Fund. Once regulators have earmarked a certain percentage of the fund to cover administration costs for the state’s nascent adult-use program, 39% would go to a general fund, 30% to public education grants, and 20% would go to programs for substance misuse treatment and prevention.

Another 10% would go to the State Judicial Revolving Fund while 10% would be divided among the municipalities where cannabis sales took place. The measure would also have provisions to allow people with cannabis convictions to file for reversal of conviction, modification of judgment and sentence, resentencing or dismissal of case.

With around 60,000 Oklahomans currently estimated to have cannabis-related criminal charges on their records, the measure could have a major impact if it passes.

Former Oklahoma representative Ryan Kiesel added that the law would grant law enforcement with new tools to go after the cannabis black markets and illegal players within the state.

Oklahoma senior U.S. Sen. James Lankford, who remains opposed to cannabis legalization, urged Oklahomans to protect their communities and families by voting against the measure.

If this measure gains voter approval, Oklahoma could present additional opportunities to enterprises such as REZYFi Inc. which has focused on stepping up to give cannabis companies the funding they need in an environment where mainstream banks aren’t willing to do business with players in this industry.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi Inc. are available in the company’s newsroom at https://cnw.fm/REZY

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Alaskan Supreme Court Announces Plan to Expunge Cannabis Possession Criminal Records

The Alaska Supreme Court has announced that it would expunge cannabis convictions from the records of hundreds of Alaskans. An order signed by five Supreme Court justices revealed that the court would remove the cannabis possession convictions of 750 residents from the online court case database.

However, rather than completely expunge certain cannabis records, the court will simply shield them from public view. So while the general public would likely find it hard to see these records, the records will still be accessible for inspection at courthouses and via formal criminal background checks.

Only Alaskans who were aged 21 and older when they were convicted of possession of an ounce or less of cannabis will be eligible for the removal.

Alaska Court System general counsel Nancy Meade said that since cannabis has been legal in the state for eight years, the Supreme Court thought that it was not appropriate for people to suffer the negative consequences of having a conviction attached to their name on Courtview, the state’s online database of court cases.

Now that most states have legalized cannabis in some form, reform activists and lawmakers argue that it is wrong for people with cannabis convictions to continue being penalized for certain cannabis offenses.  A criminal record can significantly impact your life in the United States by making it difficult to access employment, housing and education.

Obscuring, sealing or expunging nonviolent cannabis offenses from people’s records could shield people from the negativity associated with a criminal record and allow them to access critical services such as housing.

Rep. Stanley Wright says that there are a lot of people in his district who are held back by the barriers created by a publicly visible criminal record. A simple policy change or legislation could remove these barriers and change their whole lives, Wright said.

Sen. Scott Kawasaki was happy with the move and stated that he was glad the Supreme Court had ordered the removal of certain cannabis offenses from public view. Wright has joined nearly half a dozen independent and Democratic cosponsors in reintroducing a bill that would conceal cannabis convictions from criminal background searches and Courtview.

Alaska joins a growing number of states that are moving to either obscure or expunge marijuana-related convictions. The National Conference of State Legislatures reports that 41 states in total have passed some form of regulation to obscure nonviolent, cannabis-related convictions.

These actions by the state Supreme Court peel back some of the vestiges of prohibition and send positive signals to allied industry actors such as Advanced Container Technologies Inc. (OTC: ACTX) since increased growth of the industry opens opportunities for these related companies.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — SAMHSA Advisory Warns Users About CBD, Suggests Dispensary-Sourced Products Could Be Safer

The Substance Abuse and Mental Health Services Administration (SAMHSA), a branch of the U.S. Department of Health and Human Services, has released a new advisory warning about the possible side effects, harms, and unknowns of CBD. The federal agency also makes the implication that cannabis dispensaries may sell safer products than gas stations and other stores.

The cannabinoid product has been available on store shelves since Congress approved the use of hemp in the 2018 Farm Act, and SAMHSA reports that demand for it is still rising. According to SAMHSA’s advisory, a variety of form factors, such as CBD-infused foods, topicals, fabrics and drinks, are now available at an estimated 270,000 retail stores countrywide.

According to the advisory, which quotes a survey done by prescription discount plan SingleCare, one in every three Americans reported using cannabinoid products in 2020. As a result of its widespread use, the agency urges that people be aware of the risks and dangers involved with using CBD products as well as the common misconceptions surrounding them.

A majority of the risks mentioned in the study, including inaccurate labeling, poor quality control and low safety standards, are brought on by the fact that CBD products are not federally regulated.

The FDA announced last month that it would not be developing rules to permit the marketing of CBD as a food or dietary supplement despite numerous requests for action from legislators, advocates and other stakeholders to do so. Instead, it declared that it would prefer to work with Congress to find a different course of action. Additionally, the agency denied citizen petitions asking for rulemaking on CBD marketing.

The warning makes no attempt to contrast CBD’s potential side effects with the problems associated with prescription drugs, such as opioids. Various studies have shown that the use of opioids to treat conditions such as chronic pain can be decreased by making regulated marijuana, including CBD products, more widely available.

Epidiolex, a prescription drug made of purified CBD that is meant to treat a rare type of childhood epilepsy, is the only CBD product that has received FDA approval to date. All other CBD products are sold as potential treatments for a range of medical conditions, with only a few having been proven effective through research.

According to survey results from 2019 cited by the agency, 40% of CBD users bought products from cannabis dispensaries. One-third of consumers (34%) received the products from retail locations while 27% bought it online and 12% got it from an undisclosed source.

While marijuana dispensaries are still illegal on the federal level, cannabis retailers, which are typically licensed and subject to strict state regulation, may provide better and more consistent CBD products than those offered by national retailers, according to SAMHSA. However, the organization also stated that depending on the state’s definition of acceptable CBD products, the goods sold at marijuana dispensaries that are not FDA approved may contain more than 0.3% THC.

The medicinal potential of cannabis has drawn the attention of many entities, such as India Globalization Capital Inc. (NYSE American: IGC), which have invested heavily into studying these substances with the aim of commercializing FDA-approved formulations from them.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

India Globalization Capital Inc. (NYSE American: IGC) Leads the Way Forward with Revolutionary Cannabis-Based Treatment for Alzheimer’s Symptoms

  • Company’s investigational drug is being tested for the first time ever on humans in an FDA-approved study
  • In phase 1 studies, IGC-AD1 shows potential to safely reduce debilitating symptoms
  • IGC is actively building a portfolio of both cannabis-based and manufactured molecules that can address multiple areas of unmet medical needs

In groundbreaking work that establishes its commitment to being a pioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study (https://cnw.fm/6qps2). The company is developing its proprietary treatment, IGC-AD1, hoping to provide relief to the 55 million people worldwide struggling with agitation in dementia that results from Alzheimer’s.

IGC is focused on revolutionizing the treatment of Alzheimer’s with its game-changing treatment. In phase 1 studies, IGC-AD1 shows potential to safely reduce the debilitating symptoms that impact millions of Alzheimer’s patients and their caregivers. Featuring a low dose of THC, the treatment is the first natural cannabis-based investigational drug being tested in human FDA trials to treat Alzheimer’s patients; it provides medical benefits without psychoactive effects. “As millions of Alzheimer’s patients continue to suffer from agitation, anxiety, and depression, phase 2 clinical trials bring hope for a treatment,” the company reports.

In addition to IGC-AD1, IGC is actively building a portfolio of both cannabis-based and manufactured molecules that can address multiple areas of unmet medical needs (https://cnw.fm/67wqT). The company’s TGR-63 product is being studied for its potential to decrease Alzheimer’s markers, including plaque buildup, while also decreasing cognitive decline and improving memory. The company also has undisclosed molecules involved in exploratory activities.

With no current FDA-approved drugs to treat in Alzheimer’s patients, the company clearly has found a place where it can establish a foothold. In fact, last year less than 7% of drugs in clinical trials were focused on treating neuropsychiatric symptoms of Alzheimer’s. The time has clearly come for IGC. “What we do is important,” the company states. “With no known cure, our formulations have the potential to change lives.”

IGC develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s disease, Parkinson’s disease, chronic pain, and even pet seizures. The company sells various brands of CBD-based consumer products, including Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage. The company operates facilities in the United States under Good Manufacturing Practices.

For more information, visit the company’s website at www.IGCPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Arizona Records $1.4B in Cannabis Sales in 2022

The total marijuana sales in Arizona in 2022 were similar to those in 2021, the first year the drug was legal for adult use, but the routes by which each year’s sales reached $1.4 billion were remarkably different. In 2021, medical cannabis sales accounted for $760 million, or nearly 55% of total sales. In 2022, recreational marijuana took the lead, accounting for roughly 70% of total sales, totaling more than $950 million. The medical cannabis market has dropped to just over $500 million.

Recreational cannabis sales ended 2022 with its best monthly total in December, totaling about $86.6 million, a small increase from the $85.8 million in the previous month. The monthly sales of medical marijuana remained stable, falling from $31.9 to $31.1 between November 2022 and December 2022.

Since the beginning of the legalization of adult-use in January 2021, cannabis sales have totaled $2.9 billion in both markets. Since April 2021, medical sales have decreased almost every month, with a few exceptions, such as July, when sales reached $71.6 million following a $5 million decline in June.

Patients continue to swarm to the recreational market, and producers of edibles and other ingestible products with higher potencies for medical use have started to cater to this market. The first full month of licensed recreational sales, February 2021, saw the lowest total sales for adult-use at around $40 million.

Medical marijuana patients pay about 6% in tax, while the state collects an additional 16% excise tax on recreational purchases in addition to the regular sales tax. Local governments add about 2% of the taxes. December saw a total of almost $23 million in tax collections.

A third of the taxes collected from recreational sales are committed to community colleges, with 25% earmarked for the Highway User Revenue Fund, another one-third to public safety — fire departments, police, and first responders — and 10% to the Justice Reinvestment Fund, which is committed to providing counseling services, job training, public health, and other social services for marginalized groups adversely affected by cannabis criminalization and arrests.

The monthly reports on the medical program are typically published one month prior by the state’s health services department (ADHS), which is responsible for the state’s cannabis regulation, before the reports from the revenue department.

As of January, there were 153,845 cardholders overall, with 128,621 of them being eligible patients. According to ADHS, those figures decreased by about 1,200 in December 2022, to 155,682 and 129,836, respectively. The state’s cardholders are divided into five groups: qualified patients, dispensary agents, designated caregivers, lab agents, and facility agents.

Those figures contrast sharply with the situation with medical marijuana at the start of 2021, when recreational sales started.

At that time, 309,479 people had medical cards, according to data from ADHS in January 2021. The number of qualified patients and dispensary agents was 299,054 and 9,489, respectively.

In terms of the quantities sold in January, the weight stood at 5,435 pounds, with flower at 4,645 pounds, and the rest accounted for other forms such as edibles.

As these marijuana sales figures climb, there is likely to be a commensurate increase in the use of cultivation equipment such as that sold by Advanced Container Technologies Inc. (OTC: ACTX), given that rising sales point to an increase in the produce being cultivated and processed.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — California’s Yearly Marijuana Sales Decline for First Time Since Launch of Recreational Market

New data from the California Department of Tax and Fee Administration shows that annual marijuana sales in the state dropped in 2022.  This is the first time since the state launched its recreational market five years ago that sales have fallen.

Last year, retailers raked in $5.3 billion in taxable sales of medical and recreational cannabis. This is quite a drop, in comparison to the $5.8 billion generated in 2021. Taxable sales in the fourth quarter also declined to $1.3 billion, down by almost 12% from the same period in 2021.

Hirsh Jain, Ananda Strategy’s founder, stated that the continued lack of retail outlets in various regions in the state along with low wholesale prices were the main drivers of this trend. Low wholesale prices make marijuana products cheaper for consumers. Ananda Strategy is a consultancy that advises leading marijuana retailers, brands and venture capital funds.

The marijuana industry consultant further observed that the state’s dual-licensing system had also made it harder for new dispensaries to launch since the recreational use of marijuana was permitted. Jain noted that this had limited the size of California’s legal marijuana market, causing it to plateau prematurely and regress.

California was the first state in the country to legalize the medical use of marijuana, after voters approved in the Compassionate Use Act in 1996.

Under California’s law, marijuana enterprises must acquire local authorization from the county/city they operate in before they can submit their application for a state license. This has caused delays in license issuance, which is affecting operators in different parts of the state, including Mendocino County.

In a letter penned earlier this month to Governor Gavin Newsom of California and Director Nicole Elliott of the Department of Cannabis Control, the Mendocino Cannabis Alliance called for regulators to step in as local governments hadn’t succeeded in establishing a process that could move good-faith marijuana operators towards annual licensure in the state.

California’s illegal market may have also affected sales at licensed retailers, a trend which emerged in the years before voters in the state legalized adult-use sales and possession in November 2016. Industry players estimate that the illicit market is twice the size of the regulated marijuana industry.

Marijuana businesses in the state also brought in roughly $1.1 billion in taxes last year, a more than 20% drop from 2021’s $1.4 billion. Experts believe the decrease partly arose from the scrapping of California’s cultivation tax, as well as the aforementioned regulatory and economic challenges.

It would be interesting to look into how this decline in cannabis sales in California is impacting companies such as REZYFi Inc. which specialize in funding marijuana companies in different jurisdictions.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi Inc. are available in the company’s newsroom at https://cnw.fm/REZY

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – REZYFi Inc. Using Diversified Approach to Capitalize on Growth in Multiple Verticals

REZYFi, which is positioned as one of the first cannabis mortgage bankers in the United States, is servicing the needs of both traditional and non-traditional consumers and businesses. “The company targets markets that include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individuals seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings. Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending and ResMac Inc.,” a recent article reads. “Through REZYFi Lending, the company leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA and VA loans, reverse mortgages, jumbo loans, and adjustable-rate mortgages… REZYFi’s second wholly-owned subsidiary, ResMac, has been operating for 13 years. It has closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operation for 2023. REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals.”

To view the full article, visit https://cnw.fm/KT2gQ

About REZYFi Inc.

REZYFi is a cannabis-focused mortgage origination and specialized financing company in the U.S. The company originates, structures and invests in first mortgage loans and alternative structured financings secured by commercial and residential real estate properties. For more information, visit the company’s website at REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://cnw.fm/REZY

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Encouraging Results from DehydraTECH-CBD Diabetes Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its diabetes animal model study DIAB-A22-1 has completed and produced at least three positive outcomes including weight loss in obese diabetic-conditioned animals, together with improved triglyceride and cholesterol levels. According to the update, the study evidenced, at times, dramatic changes in body weight, general activity and triglyceride and cholesterol levels associated with administration of DehydraTECH-CBD. The findings align well with other study work in animals that points to the known anti-inflammatory and antioxidant properties of CBD functioning to lessen some of the essential pathophysiological factors associated with diabetes. Pleased that relatively low doses of DehydraTECH-CBD seem to support real improvements in the day-to-day health of the lab animals, Lexaria is encouraged by the positive findings from its first study of DehydraTECH-CBD in this diabetes animal model. The findings indicate many prospective benefits worthy of further investigation, perhaps together with other drugs that further help to control glucose levels directly.

To view the full press release, visit https://cnw.fm/1ihUn

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Sugarmade Inc. (SGMD) Names New Board, Audit Committee Member

Sugarmade (OTC: SGMD), a product and branding marketing company investing in operations and technologies with disruptive potential, has appointed Darren Kenney as a new independent director and audit committee member. In the announcement, Sugarmade noted that it is focusing on an aggressive growth strategy and is looking to Kenney and his expertise to ensure the accuracy and integrity of company financial affair. An experienced CPA and licensed real estate broker in California, Kenney has built and sold three accounting practices over the past three decade; he has also served as a consultant with GTE (now Verizon), Saks Fifth Avenue and CalTrans. “This is another important step toward fulfilling the uplisting requirements to advance Sugarmade onto the OTCQB exchange as well as an essential factor in expanding our accounting and reporting capabilities as we pursue new acquisitions and prepare for a future uplisting onto the NASDAQ exchange,” said Sugarmade CEO Jimmy Chan in the press release.

To view the full press release, visit https://cnw.fm/LaOrY

About Sugarmade Inc.

Sugarmade is a product and branding marketing company investing in operations and technologies with disruptive potential. The company’s brand portfolio includes CarryOutsupplies.com, SugarRush(TM), J Grade Farm and Lemon Glow. For more information about the company, please visit www.Sugarmade.com.

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://cnw.fm/SUGAR

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Disrupt Drug Delivery Through Innovation

  • Lexaria’s DehydraTECH(TM) technology has 28 granted patents, with many more patents pending worldwide
  • DehydraTECH(TM) uses a patented formulation and dehydration process method to change how the body detects and absorbs drugs
  • Lexaria is focusing on three main areas: CBD for hypertension, oral nicotine to replace vaping and smoking, and CBD potentially for diabetes and seizures
  • Lexaria is conducting early work to support its FDA-registered IND program to investigate DehydraTECH(TM)-processed CBD for hypertension

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability and improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through its patented proprietary technology, DehydraTECH(TM). DehydraTECH is applied to multiple ingestible product formats, such as tablets, capsules, oral suspensions, mouth melts, and others, with opportunities for success in cannabinoids, nicotine, antivirals, and other APIs. To date, Lexaria has 28 granted patents, with many more patents pending worldwide.

Lexaria’s DehydraTECH uses a patented formulation and dehydration processing method that changes how the body detects and absorbs drugs. The DehydraTECH process is beneficial to the end user because it speeds up onset, increases bioavailability, improves drug potency, eliminates the need for sugar-filled edibles, lowers dosage, and lowers administration costs.

In 2023, the company is focused on three main areas: cannabidiol (“CBD”) for hypertension, oral nicotine to replace vaping and smoking, and other applications for DehydraTECH-CBD such as diabetes and seizures. Lexaria has yielded several studies that have proven beneficial for its research and development efforts, including five human clinical trials completed involving DehydraTECH-CBD.

HYPER-H21-4 consisted of male and female volunteers between the ages of 40-70 with documented or measured elevated blood pressure. Participants received DehydraTECH-CBD every day for a 5-week duration, with doses escalating between 225 mg/day to 450 mg/day over the course of the study, adjusted relative to body weight. Some participants were already using the industry standard of care for hypertension, allowing Lexaria to study the efficacy and safety of DehydraTECH-CBD with and without other hypertension treatments. The extended duration of the study allowed Lexaria to gather critical data to evaluate the potential for long-term health benefits of its DehydraTECH-CBD formulation.

“Given that these were the primary objectives of the study, it is accurate to say that HYPER-H21-4 was a success,” Lexaria CEO Chris Bunka said in his annual letter to shareholders recently (https://cnw.fm/fXTep). “In addition, a series of secondary study objective evaluations, as previously announced, are in progress, and these findings will be released in due course if any of them are notable.”

Lexaria expects to launch its FDA-registered IND program to investigate DehydraTECH-CBD for hypertension formally. The program is a large undertaking, one that will dominate the second half of 2023 and beyond – the company expects to conduct fewer additional smaller studies than they have in years past due to the focus required for this study. Preparatory work for this Phase 1b study is well underway.

“We continue to enjoy more successes than failures. We’re hopeful that our commercial endeavors might obviate any need to raise capital via equity issuance at current market levels, and our tight fiscal controls have greatly assisted in that pursuit,” Bunka also said. He added that the company will explore various commercial arrangements in 2023 in order to increase cash flow, while also continuing efforts to build and enhance its client base.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.